Open AccessLack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Author(s) -
Daniel Camprubí,
Alex Almuedo-Riera,
Helena Martí-Soler,
Álex Soriano,
Juan Carlos Hurtado,
Carme Subirá,
Berta Grau-Pujol,
Alejandro Krolewiecki,
José Muñóz
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0242184
Subject(s) - ivermectin , medicine , covid-19 , clinical trial , randomized controlled trial , virology , veterinary medicine , disease , outbreak , infectious disease (medical specialty)
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom